Key Details
Annual EPS
-$20.80Annual ROE
-145.64%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
June 07, 2024Recent annual earnings:
Dec 23, 2021Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
June 15, 2023Analyst ratings
Recent major analysts updates
21 Oct '22 Oppenheimer
Perform18 Oct '22 RBC Capital
Sector Perform17 Oct '22 Chardan Capital
Neutral12 Aug '22 Chardan Capital
Buy31 May '22 HC Wainwright & Co.
Buy13 May '22 Chardan Capital
Buy01 June '21 HC Wainwright & Co.
Buy12 Feb '21 HC Wainwright & Co.
Buy16 June '20 RBC Capital
Outperform01 Apr '20 Oppenheimer
OutperformScreeners with NBSE included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
NeuBase Therapeutics doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?
NBSE
InvestorPlace26 March 2024
NeuBase Therapeutics (NASDAQ: NBSE ) stock is falling on Tuesday after the company announced details for an upcoming special shareholder meeting. The big news here is that NeuBase Therapeutics is seeking shareholder approval for the liquidation and dissolution of the company.
NeuBase (NBSE) Surges 107% on New Shareholder Acquiring Stake
NBSE
Zacks Investment Research07 September 2023
With NeuBase (NBSE) exploring strategic alternatives to the company, Symetryx joins the company's shareholder base and urges the board to issue a unique $1 per share dividend.
Why Is NeuBase Therapeutics (NBSE) Stock Up 19% Today?
NBSE
InvestorPlace06 September 2023
NeuBase Therapeutics (NASDAQ: NBSE ) stock is taking off on Wednesday despite a lack of news from the preclinical biopharmaceutical company. There are no new press releases from NeuBase Therapeutics or filings with the Securities and Exchange Commission (SEC) that explain why the stock is up today.
FAQ
- What is the primary business of NeuBase Therapeutics?
- What is the ticker symbol for NeuBase Therapeutics?
- Does NeuBase Therapeutics pay dividends?
- What sector is NeuBase Therapeutics in?
- What industry is NeuBase Therapeutics in?
- What country is NeuBase Therapeutics based in?
- When did NeuBase Therapeutics go public?
- Is NeuBase Therapeutics in the S&P 500?
- Is NeuBase Therapeutics in the NASDAQ 100?
- Is NeuBase Therapeutics in the Dow Jones?
- When was NeuBase Therapeutics's last earnings report?
- When does NeuBase Therapeutics report earnings?
- Should I buy NeuBase Therapeutics stock now?
What is the primary business of NeuBase Therapeutics?
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
What is the ticker symbol for NeuBase Therapeutics?
The ticker symbol for NeuBase Therapeutics is NASDAQ:NBSE
Does NeuBase Therapeutics pay dividends?
No, NeuBase Therapeutics does not pay dividends
What sector is NeuBase Therapeutics in?
NeuBase Therapeutics is in the Healthcare sector
What industry is NeuBase Therapeutics in?
NeuBase Therapeutics is in the Biotechnology industry
What country is NeuBase Therapeutics based in?
NeuBase Therapeutics is headquartered in United States
When did NeuBase Therapeutics go public?
NeuBase Therapeutics's initial public offering (IPO) was on 28 May 2004
Is NeuBase Therapeutics in the S&P 500?
No, NeuBase Therapeutics is not included in the S&P 500 index
Is NeuBase Therapeutics in the NASDAQ 100?
No, NeuBase Therapeutics is not included in the NASDAQ 100 index
Is NeuBase Therapeutics in the Dow Jones?
No, NeuBase Therapeutics is not included in the Dow Jones index
When was NeuBase Therapeutics's last earnings report?
NeuBase Therapeutics's most recent earnings report was on 7 June 2024
When does NeuBase Therapeutics report earnings?
The date for NeuBase Therapeutics's next earnings report has not been announced yet
Should I buy NeuBase Therapeutics stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions